# A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

> **NCT06710847** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 14 (actual)

## Conditions studied

- Neoplasms, Colorectal
- Solid Tumor
- Colon Cancer
- Rectal Cancer
- Endometrial Cancer

## Interventions

- **DRUG:** GSK4418959
- **BIOLOGICAL:** PD-1 inhibitor

## Key facts

- **NCT ID:** NCT06710847
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-13
- **Primary completion:** 2026-06-22
- **Final completion:** 2026-06-22
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06710847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06710847, "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06710847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*